BXRXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BXRXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Baudax Bio's Sloan Ratio for the quarter that ended in Sep. 2023 was 0.00%.
Warning Sign:
When sloan ratio (-308.83)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Sep. 2023, Baudax Bio has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
The historical data trend for Baudax Bio's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baudax Bio Annual Data | |||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Sloan Ratio % | Get a 7-Day Free Trial | -29.88 | 34.99 | -45.69 | 55.74 | -308.83 |
Baudax Bio Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Sloan Ratio % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Baudax Bio's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Baudax Bio's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Baudax Bio's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Baudax Bio's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2022 ) | - | Cash Flow from Operations (A: Dec. 2022 ) |
- | Cash Flow from Investing (A: Dec. 2022 )) | / | Total Assets (A: Dec. 2022 ) | |
= | (-58.795 | - | -27.793 | |
- | -0.02) | / | 10.032 | |
= | -308.83% |
Baudax Bio's Sloan Ratio for the quarter that ended in Sep. 2023 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Sep. 2023 ) | |
= | (-7.154 | - | -14.306 | |
- | 0) | / | 20.583 | |
= | 34.75% |
Baudax Bio's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was -9.249 (Dec. 2022 ) + 11.404 (Mar. 2023 ) + -7.375 (Jun. 2023 ) + -1.934 (Sep. 2023 ) = $-7.15 Mil. Baudax Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 was -3.783 (Dec. 2022 ) + -4.664 (Mar. 2023 ) + -3.446 (Jun. 2023 ) + -2.413 (Sep. 2023 ) = $-14.31 Mil. Baudax Bio's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 was 0 (Dec. 2022 ) + 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baudax Bio (OTCPK:BXRXQ) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2023, Baudax Bio has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Thank you for viewing the detailed overview of Baudax Bio's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Natalie Mcandrew | officer: Interim CFO | C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355 |
Yong Chan Kim | director | C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355 |
Winston J Churchill | director | C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Andrew T Drechsler | director | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Arnold M Baskies | director | 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003 |
Wayne Weisman | director | 490 LAPP ROAD, MALVERN PA 19355 |
Jillian Dilmore | officer: Corporate Controller/Secretary, other: PFO and PAO | C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355 |
Geraldine Henwood | director, officer: President and CEO | 88 SIDNEY ST, CAMBRIDGE MA 02139 |
Richard S Casten | officer: Chief Financial Officer | 490 LAPP ROAD, MALVERN PA 19355 |
Alfred Altomari | director | C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
Ryan David Lake | director, officer: Chief Financial Officer | KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341 |
Recro Pharma, Inc. | 10 percent owner | 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341 |
From GuruFocus
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 05-12-2023
By GuruFocus Research • 02-13-2024
By GuruFocus Research • 02-13-2024
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 06-30-2023
By sperokesalga sperokesalga • 04-24-2023
By Marketwired • 08-17-2023
By Marketwired • 08-16-2023
By Marketwired • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.